Qiming Venture Partners Weekly | Portfolio Company Updates Vol. 34, 2025
Tracking milestone moments with you for Qiming Venture Partners' portfolio companies
Editor's Note: The "Qiming Weekly" column is published regularly every week, rounding up funding news and development updates from Qiming Venture Partners' portfolio companies.
In the wave of technology and innovation, every step entrepreneurs take deserves to be recorded. Qiming Venture Partners will continue to accelerate and empower entrepreneurs, and we invite you to join us in marking the milestone moments of our portfolio companies.
IPO
Hesai Technology, Global Leader in 3D LiDAR Solutions, Completes Dual Primary Listing on Hong Kong Exchanges and Clearing
On September 16 Beijing time, Qiming Venture Partners portfolio company and NASDAQ-listed Hesai Technology (NASDAQ: HSAI, 02525.HK) completed its dual primary listing on Hong Kong Exchanges and Clearing. Hesai Technology, a global leader in 3D LiDAR solutions, priced its offering at HK$212.8 per share, achieving a market capitalization of HK$32.6 billion.
Qiming Venture Partners has long tracked innovation and transformation in the autonomous driving sector. Qiming participated in Hesai Technology's Series C financing in 2019 and continued its investment in the Series D round.
Founded in 2014, Hesai Technology's core business is the design, research, development, manufacturing, and sales of advanced LiDAR products. Leveraging advanced application-specific integrated circuit (ASIC) and other LiDAR-related technologies, proprietary in-house design and production capabilities, and a platform-based architecture, Hesai Technology delivers LiDAR products that balance performance, quality, and cost to the growing advanced driver-assistance systems (ADAS) and robotics markets.
Dr. Kai Sun, Hesai Technology co-founder and chief scientist, said: "Over the past decade, through chip-based architecture and automated production systems, Hesai Technology has reduced LiDAR from $100,000 devices limited to research institutions to $200 units, achieving mass deployment in millions of vehicles and bringing advanced safety and intelligent technology to the general public. Looking ahead to the next decade, the fourth industrial revolution centered on AI has quietly arrived. The leap in social productivity will significantly improve human life, and Hesai Technology will provide new core technologies and products for this new era. Great technology should enhance everyone's life. Hesai Technology's Hong Kong stock code is 2525. We hope the company's contribution to the new era will be remembered by people 500 years from now, as this string of numbers symbolizes, to inspire all Hesai people to advance, advance, and advance further."
Corporate ESG
Meituan and Xiaomi Named to Forbes China's 2025 China ESG 50 List and ESG Inspiration Cases
Recently, Forbes China released its third annual ESG 50 list and ESG Inspiration Cases, aiming to provide deep insight into companies' practical achievements and innovative exploration in ESG (environmental, social, and governance). Qiming Venture Partners portfolio companies Meituan (03690.HK) and Xiaomi (01810.HK) were named to the Forbes China · 2025 China ESG 50, with Xiaomi also selected as an ESG Inspiration Case.
This year, the ESG 50 list selected 50 Chinese companies from the 2025 Forbes Global 2000 list that have achieved breakthroughs in compliance and innovation, globalization and localization, while 10 reference cases were chosen from nearly 100 submissions. The list focuses on pioneering enterprises in critical areas such as nature-social system integration and AI governance, aiming to map out new pathways for sustainable development in China.
Major Partnerships
01/
UBTECH Signs Exclusive Distribution Agreement with Stellar Intelligence Technology to Expand in Southeast Asia
Amid accelerating global development in the intelligent robotics industry, Singapore-based Stellar Intelligence Technology (hereinafter "Stellar Intelligence Technology") recently signed an exclusive distribution agreement with Qiming Venture Partners portfolio company UBTECH (09880.HK) for large-scale humanoid robot products, becoming UBTECH's partner in the Singapore and Malaysian markets.
UBTECH is a leader in humanoid robots and a pioneer in intelligent service robots, with full-stack humanoid robot technology and Embodied Artificial Intelligence core technology. It holds the world's largest number of effective humanoid robot patents and was the first to achieve commercial deployment of humanoid robots. It is also the only humanoid robot company globally to have announced partnerships with multiple automakers, with its Walker S series becoming the industrial humanoid robot deployed in the most automotive factories worldwide. Through this partnership with Stellar Intelligence Technology, UBTECH will use Singapore and Malaysia as a springboard to expand into Southeast Asia and accelerate its global footprint.
02/
Infinigence AI and Shanghai Innovation Institute Establish Joint Industry-Academia Laboratory
At the first SII TechFest 2025 and Shanghai Innovation Institute's first anniversary celebration, Qiming Venture Partners portfolio company Infinigence AI and Shanghai Innovation Institute jointly signed a Framework Agreement for Joint Laboratory Construction, announcing the establishment of the "SII-Infinigence Intelligent Terminal Joint Laboratory."
The "SII-Infinigence Intelligent Terminal Joint Laboratory" will focus on frontier artificial intelligence technology, particularly innovation in edge intelligence, and is committed to continuously enhancing the industrial application value of cutting-edge R&D through a collaborative industry-research technology innovation mechanism. Going forward, the joint laboratory will follow the principles of "complementary strengths, collaborative innovation, resource sharing, and mutual development," focusing on the AI field and carrying out industry-academia cooperation across three main areas: joint cultivation of high-level scientific research and engineering talent, building efficient scientific research and technology transfer mechanisms, and establishing collaborative industry innovation and R&D systems.
03/
Yanyin Technology and East Sunshine Pharmaceutical Enter Strategic Partnership
Recently, Qiming Venture Partners portfolio company Yanyin Technology and East Sunshine Pharmaceutical formally announced a strategic partnership. The two sides will collaborate deeply on R&D AI agents, using an AI translation agent project as a starting point to develop solutions covering core scenarios including experimental design and IND filing, as well as AI laboratory automation robotics. Together they will explore deep applications of AI technology across the full drug R&D pipeline, accelerating East Sunshine Pharmaceutical's globalization strategy.
Dr. Zeping Chen, founder and CEO of YanYin Technology, said: "We are deeply honored to earn the trust and recognition of an industry benchmark like East Sunshine Pharmaceutical. Winning out in such a competitive process is a strong validation of our team's technical capabilities and service philosophy. We will fully support East Sunshine Pharmaceutical's global operations, leveraging cutting-edge AI technology to enhance their R&D and operational efficiency. This is only the beginning. We look forward to working hand in hand with East Sunshine Pharmaceutical to explore the boundless possibilities of AI in biomedicine, and to contribute greater value to the industry's advancement."
04/
YanYin Technology and Epigenetix Enter Strategic Partnership
Recently, two Qiming Venture Partners portfolio companies — YanYin Technology and Epigenetix — formally announced a strategic partnership. The two sides will collaborate deeply on laboratory digital management and intelligent upgrading. Epigenetix will adopt the Electronic Lab Notebook (ELN) and materials inventory management modules from YanYin Technology's "YanYin Zhiyan Cloud" platform, to enhance its R&D efficiency and data management capabilities in the field of gene-regulation therapeutics.
Dr. Baohong Zhang, co-founder and CEO of Epigenetix, said: "Epigenetix is a biotechnology company focused on treating various chronic diseases through epigenetic regulation technology. The company concentrates on our core R&D platform and delivery technology, and over the past few years, multiple pipelines have successively entered clinical stages. YanYin Technology is a builder of R&D digitalization and standardization systems, as well as an industry leader. We hope that through deeper cooperation with YanYin Technology, from the perspective of AI empowerment, we can achieve win-win cooperation and mutual development."
Dr. Zeping Chen, founder and CEO of YanYin Technology, said: "We are deeply honored to earn Epigenetix's trust and selection. Epigenetix possesses profound scientific research strength and tremendous growth potential in the cutting-edge field of epigenetics. YanYin Technology remains committed to empowering biopharmaceutical enterprises through AI and digital tools. We believe that YanYin Zhiyan Cloud will become a powerful assistant to Epigenetix's R&D team, and we look forward to this collaboration becoming a model of how AI technology can help innovative pharmaceutical companies grow, jointly contributing to the advancement of life sciences."
05/
Children's Hospital of Chongqing Medical University Partners with ZUOYI Tech to Build Pediatric AI Family Doctor
At the 2025 World Intelligence Expo, "Chonger · Xiaoyi" — a pediatric AI family doctor jointly developed by Children's Hospital of Chongqing Medical University and Qiming Venture Partners portfolio company ZUOYI Tech — was officially launched.
"Chonger · Xiaoyi" represents ZUOYI Tech's latest breakthrough in smart healthcare. Built on the "Qianyi Huier" large model developed in collaboration with Children's Hospital of Chongqing Medical University, it deeply integrates the hospital's authoritative medical resources to create a 24/7 online children's health guardian expert.
R&D Progress
RingNovo's World-First Absorbable Spacer Hydrogel for Cervical Cancer Radiotherapy Published in Top International Journal
Recently, clinical research on the world's first "absorbable spacer hydrogel" for cervical cancer radiotherapy — led by Professor Fuquan Zhang of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, and jointly completed with nine domestic cervical cancer radiotherapy centers — was published in the top international journal International Journal of Radiation Oncology, Biology, Physics. The study used Respacio® Absorbable Spacer Hydrogel, independently developed by Qiming Venture Partners portfolio company RingNovo, and with solid Phase 3 clinical data confirmed its efficacy and safety in cervical cancer radiotherapy, bringing a breakthrough advance to the field and demonstrating the innovative strength of Chinese medical technology enterprises.
Respacio® Absorbable Spacer Hydrogel offers three core technical advantages: First, its Ready-To-Use (RTU) design requires no preoperative dissolution or preparation — it can be directly mixed and injected, making it convenient and efficient to use. Second, through CT-guided posterior vaginal wall puncture or ultrasound-guided perineal puncture, precise injection can be achieved with flexible and efficient operation. Third, the hydrogel meets radiotherapy requirements while gradually being absorbed after treatment concludes, with stable degradation that is safe and controllable.
Product Launches
01/
DK Medical's DKutting™ High-Pressure Scoring Balloon and DKaptain™ High-Pressure Balloon Launch in the United States
Recently, Qiming Venture Partners portfolio company DK Medical brought two star products — the DKutting™ High-Pressure Scoring Balloon and the DKaptain™ High-Pressure Balloon — to the U.S. market, injecting fresh momentum into the global dialysis access and peripheral vascular disease treatment fields.
This U.S. launch of the DKutting™ High-Pressure Scoring Balloon and DKaptain™ High-Pressure Balloon further completes DK Medical's product portfolio layout in the global dialysis access and peripheral vascular disease treatment space. It represents not only high recognition of DK Medical's product performance and quality, but also an important milestone in the company's expansion into global medical markets and promotion of international medical collaboration.
02/
DeepWise Officially Launches NMR-Solver, an Intelligent Analysis System for Nuclear Magnetic Resonance Spectroscopy
Recently, Qiming Venture Partners portfolio company DeepWise officially launched NMR-Solver, an intelligent analysis system for nuclear magnetic resonance spectroscopy, alongside a technical report.
Leveraging a hundred-million-level molecular spectrum database, advanced optimization algorithms, and deep learning models, NMR-Solver achieves intelligent parsing of NMR spectra and automated inference of molecular structures. To meet researchers' demand for "zero deployment, immediate use," a one-stop web application was simultaneously launched, delivering a convenient and efficient new user experience. As an innovative tool in the characterization and analysis pipeline, NMR-Solver will inject new acceleration into frontier research in synthetic chemistry, drug discovery, and other fields, further promoting deep integration of experimentation and computation, and significantly enhancing scientific research and production efficiency.
Tech Strength
01/
WeRide Expands European Footprint
Autonomous Minibus Debuts in Belgium
WeRide (NASDAQ: WRD), a Qiming Venture Partners portfolio company, recently announced the deployment of its autonomous minibus Robobus (hereinafter referred to as "WeRide Robobus") in Leuven, Belgium. This marks WeRide's official entry into its eleventh global market, further expanding the company's European operations following launches in France, Spain, and Switzerland. The project is a collaboration between WeRide, Flanders public transport operator De Lijn, the City of Leuven, and mobility consultancy Espaces-Mobilités.
Effective immediately, the WeRide Robobus will commence testing preparations for the Leuven Station to Heverlee route, which traverses downtown Leuven and connects multiple core transportation hubs — a typical Belgian urban traffic scenario with dense vehicle flow. Public road testing is scheduled to begin in mid-September, with safety operators on board during the initial phase. Upon successful completion of testing and approval from the Ministry of Transport, partner De Lijn expects to launch a pilot operation between mid-November 2025 and late January 2026. This will mark Belgium's first commercial deployment of autonomous vehicles in mixed, complex traffic environments, with citizens able to conveniently purchase tickets via mobile app, SMS, or subscription services.
Following the pilot, the WeRide Robobus is expected to transition to regular operations, filling the "last mile" gap in Leuven's public transit system and propelling Belgium toward a milestone in autonomous public transportation. Looking ahead, the WeRide Robobus aims to achieve fully driverless operations, further enhancing urban traffic safety and efficiency in Belgium.
02/
Hesai Technology Debuts at IAA Mobility 2025
Hesai Technology (NASDAQ: HSAI, 02525.HK), a Qiming Venture Partners portfolio company, showcased its latest generation of high-performance lidar products at IAA Mobility 2025, a premier global automotive technology event.
At this global showcase of automotive innovation, Hesai Technology unveiled a series of industry-leading high-performance lidar products powered by its exceptional chip-based innovation capabilities. Among them, the automotive-grade 800-line ultra-long-range lidar ETX set new records for mass-produced automotive lidar with its dual benchmarks of "highest line count globally" and "longest detection range globally," establishing itself as the "perception king" for L3/L4 autonomous driving. The next-generation pure solid-state automotive-grade blind-spot lidar FTX, with the world's widest field of view, fills the final perception gap for L3/L4 autonomous driving. Meanwhile, the ATX, the "standard-setter" for L2-assisted driving in best-selling vehicle models, continues to demonstrate its strong leading position in the mainstream market.
03/
Shengshu Technology Globally Launches Vidu Q1 Reference-to-Image Feature
Following the enterprise-focused commercial release of the Vidu Q1 reference-to-image solution, Shengshu Technology, a Qiming Venture Partners portfolio company, has officially opened the Q1 reference-to-image feature of its video foundation model Vidu to general users. This launch aims to help the industry overcome the technical challenge of multi-subject consistency, driving Vidu's evolution into a genuine "commercial productivity tool" and completing the closed loop from AI image generation to video generation in the commercial production chain.
Vidu Q1 reference-to-image centers on "more references, truer restoration" and features five key highlights: industry-leading reference capacity with support for up to 7 reference images simultaneously, delivering strong controllability; consistent preservation of character/subject appearance and features across multiple people, multiple scenes, and multiple generations; high-fidelity restoration that stays true to the original input while maintaining reference image characteristics, achieving true "what you see is what you get"; exceptional creative freedom, enabling outfit changes, background swaps, or free compositing with just one image and one prompt; support for multiple people in shared scenes or across multiple scenes, meeting complex narrative needs, group photos, and multi-character e-commerce applications; and 1080P high-definition resolution with enhanced Chinese semantic understanding and aesthetics tailored for local markets.
04/
Axera Technology Debuts at IAA Mobility 2025
At IAA Mobility 2025, Axera Technology, a Qiming Venture Partners portfolio company, showcased for the first time its assisted driving solution DEMO based on the M57 chip, developed in partnership with leading AI visual perception technology company STRADVISION.
This DEMO features the M57 as the main control chip, equipped with one 8-megapixel high-definition camera with a 120° horizontal field of view, and deploys STRADVISION's 3D visual perception algorithms to achieve static object detection, vehicle/pedestrian detection, lane/road boundary detection, traffic sign/signal recognition, and free space detection — supporting L2-level ADAS functions such as AEB, ACC, and LCC. Thanks to the M57 chip's excellent overall performance, the standout feature of this solution is its ability to run under ultra-low power consumption, with detection and processing performance specifically optimized for minimal power draw, making it a highly competitive offering for the global assisted driving market.
05/
HyperStrong Exhibits at RE+ 2025
At RE+ 2025, North America's premier clean energy exhibition, HyperStrong (688411.SH), a Qiming Venture Partners portfolio company, showcased its modular large-scale energy storage systems and commercial-industrial outdoor energy storage cabinets, bringing one-stop energy storage application solutions to the North American market.
HyperStrong's exhibition focused on its newly launched modular technology platform MagicBlock this year, along with the platform's first product HyperBlock M. The innovative design, outstanding performance, and supporting solution demonstrations vividly illustrated this product's high flexibility and adaptability across multiple scenarios.
06/
Pulnovo Medical's PADN Receives Two IDE Approvals and CMS Coverage
Pulnovo Medical, a Qiming Venture Partners portfolio company, recently announced that its PADN product has received two Investigational Device Exemption (IDE) approvals — including a Humanitarian Device Exemption (HDE) study for Group 1 pulmonary hypertension patients and a Premarket Approval (PMA) study for Group 2 pulmonary hypertension patients — with full coverage by the U.S. Centers for Medicare & Medicaid Services (CMS), paving the way for upcoming clinical trials in the United States.
PADN has received FDA Humanitarian Use Device (HUD) designation, National Medical Products Administration approval, and European Union CE certification, confirming its compliance with high safety and efficacy standards globally. Percutaneous Pulmonary Artery Denervation (PADN) provides additional treatment options for Group 1 pulmonary hypertension patients with limited response to existing drug therapies, as well as Group 2 pulmonary hypertension patients for whom no specific approved therapies currently exist. The PADN product has completed over 1,000 clinical applications across Portugal, Georgia, Singapore, Malaysia, China, and other countries and regions, consistently demonstrating favorable safety and therapeutic effectiveness in real-world settings.
07/
Cornerstone Robotics Debuts at the 32nd National Urological Academic Conference
At the 32nd National Urological Academic Conference (CUA2025), Qiming Venture Partners portfolio company Cornerstone Robotics unveiled its self-developed Sentire laparoscopic surgical robot and 4K3D endoscope system. Through hands-on demos, new product experiences, and live surgery broadcasts, the company showcased the technical capabilities and innovative achievements of China's high-quality surgical robots.
Cornerstone Robotics' flagship 4K3D endoscope system, launched this year, represents a major breakthrough in image quality. Built on ultra-high-definition 4K resolution and true binocular 3D imaging, paired with wide color gamut display and intelligent algorithms that eliminate vertigo, the system renders tissue microstructures with exceptional clarity, giving surgeons a realistic and clear operative field. The integrated compact console design combines the light source and image processing system in one unit, with a 5-meter extension cable to enhance surgical flexibility. One-touch 2D/3D switching and multiple intelligent automated functions streamline workflow and adapt to diverse surgical scenarios. Fiber optic transmission ensures lossless image quality, while sapphire lens protection and tin-gold welding guarantee instrument durability, meeting CF medical standards.
08/
Shenzhen Hongji Medical at the 32nd National Urological Academic Conference
During CUA2025, Qiming Venture Partners portfolio company Shenzhen Hongji Medical hosted the "Smart Endoscopy Breakthrough · Stones No More" launch event, featuring six leading urology experts who explored new approaches to stone treatment. From the clinical advantages of the innovative 6.3Fr+FANS combination, to precision diagnosis and treatment protocols for complex stone cases, to perioperative management refinements — each session zeroed in on clinical pain points, with expert insights pointing attendees toward new directions for technical breakthroughs.
Shenzhen Hongji Medical also exhibited its 6.3Fr ultra-slim flexible ureteroscope. Through extreme diameter reduction, sheathless operation, and precision high-definition technology, the 6.3Fr scope can navigate narrow ureters without pre-placed double-J stents, offering an optimal solution for emergency patients and complex cases.
09/
Rayner Vision at the 29th Chinese Ophthalmological Society Congress
At the 29th Chinese Ophthalmological Society Congress (CCOS2025), Qiming Venture Partners portfolio company Rayner Vision showcased its first domestically produced extended depth-of-focus (EDoF) IOL VisionInfinity®, its full line of intraocular lenses, eye massagers, and ultra-high-definition distance-simulation VR equipment. The company exchanged and shared the latest research findings in ophthalmology and vision science with domestic and international attendees, along with clinical product experience and future product planning.
Among these, the Jinglin Xiaobao® brain-vision training ultra-HD distance-simulation VR device was the first to obtain safety and health certification from China's National Eye Center. It employs innovative DOT and ultra-HD distance-simulation optical design, with real-time 2D/3D switching. Equipped with Sony full optical components, it delivers binocular 4K ultra-HD experience while breakthrough-achieving a simulated stable 6-10 meter distance image effect, allowing users to enjoy distance vision training in a virtual environment. This technical breakthrough offers a novel solution for adolescents' near-work eye strain and visual function issues.
10/
Xinze Source at Medical Fair Thailand 2025
At Medical Fair Thailand 2025, Qiming Venture Partners portfolio company Xinze Source presented under the theme "Technology Empowering Life," highlighting full-scenario solutions covering endoscopy, minimally invasive surgery, and veterinary medicine.
Core endoscope components including snake bones, insertion tubes, braided meshes, and control knobs — with high precision and stability — enable performance upgrades for endoscopic equipment. Consumables such as stone retrieval baskets, snares, biopsy forceps, and hemostatic clips provide full-process coverage with multi-specification customization for digestive and respiratory endoscopy scenarios. High-value surgical instruments like bone rongeurs and ultrasonic scalpels feature lightweight design and high-precision manufacturing, reducing surgical trauma, improving operational stability, and enhancing surgical efficiency. The 8015/6010/3006 series veterinary-specific endoscopes support personalized adjustment of insertion length, viewing angle, and diameter, covering both pet care and research applications.
11/
Bondent Debuts Multiple New Products and Four Solutions at FDI World Dental Congress 2025
During FDI2025 World Dental Congress, Qiming Venture Partners portfolio company Bondent unveiled multiple new products and four solution packages.
The newly launched Bondent mobile CBCT breaks through the scene limitations of traditional imaging equipment. With imaging-first coverage across multiple application scenarios, it provides mobile, high-efficiency, well-supported imaging solutions for grassroots clinics, charity screenings, and multi-site practices — becoming a major highlight of the congress.
The Pica Q dental AI intelligent auxiliary lighting system presents oral details with high-definition imaging to assist early lesion identification, supports pre- and post-operative comparison archiving; uses photos to help doctors explain and help patients easily understand treatment plans; enables long-term treatment tracking with AI-generated reports, making remote collaboration more efficient.
12/
AusperBio at the First Asian Hepatology Summit and 2025 International HBV Meeting
Recently, Qiming Venture Partners portfolio company AusperBio was invited to attend the first Asian Hepatology Summit (AHS) and the 2025 International HBV Meeting.
The Asian Hepatology Summit aims to gather top experts in hepatology from Asia and worldwide to share cutting-edge advances in liver cancer, liver transplantation, viral hepatitis, and metabolic dysfunction-associated steatotic liver disease. The International HBV Meeting focuses on breakthrough progress in hepatitis B, innovative understanding and solutions for prevention and treatment, spanning from top-tier academic sessions to small interactive workshops. Through continued active participation in international HBV conferences, AusperBio absorbs the industry's most advanced thinking, opens new avenues for collaboration and synergy, pushes the boundaries of innovation in hepatology, and works with leading experts and scholars worldwide to advance the clinical cure of hepatitis B.
13/
Benyao Technology at the 21st BCEIA
At the 21st BCEIA Beijing Conference and Exhibition on Analytical Instrumentation, Qiming Venture Partners portfolio company Benyao Technology focused on core needs for laboratory automation upgrades, highlighting its compact intelligent laboratory solution. Live demonstrations and in-depth interactions drew numerous professional visitors.
As a benchmark application for compact intelligent laboratories, the LabMate Horizon series desktop full-automation assistant innovatively combines the microliter-scale pipetting precision of the LabGenius G series pipetting robot with the millisecond-level response efficiency of the LabGenius S series transport robot, creating a "one-stop" desktop intelligent automation platform. This platform directly addresses core laboratory pain points: effectively solving problems of low manual operation efficiency, large data errors, and limited sample throughput. Its compact design cracks the industry challenge of "difficult automation upgrades in space-constrained scenarios," particularly suited for high-throughput screening in biopharmaceutical R&D and batch preprocessing in environmental sample testing, achieving "high efficiency" released from "small spaces."
Corporate Honors
01/
Gan & Lee Pharmaceuticals and Xiaomi Named Forbes China Employers of the Year
The Forbes China Best Employers rankings have been officially announced. The awards comprise China's Best Employers of the Year, China's Best Digital and Intelligent Employers, China's Best ESG Practice Employers, and China's Most Employee-Friendly Employers of the Year. Qiming Venture Partners portfolio companies Gan & Lee Pharmaceuticals (603087.SH) and Xiaomi (01810.HK) were named China's Most Employee-Friendly Employers.
The award categories were designed to reflect current trends in employer-employee relationships. Drawing on feedback gathered through open registration and surveys, the evaluation assesses companies from both employer and employee perspectives across multiple dimensions, ensuring the independence and professionalism of the rankings.
02/
Xiaomi Named to Fortune China's Most Admired Companies 2025
The Fortune China's Most Admired Companies 2025 rankings have been released. The series includes an All-Star list and industry-specific lists, recognizing companies with a long-term strategic vision. Qiming Venture Partners portfolio company Xiaomi (01810.HK) was named to an industry-specific list.
Fortune China noted that listed companies must generate profits while remaining accountable to employees, contributing to society, and protecting the environment. This "balancing capability" is what earns companies lasting recognition from markets, employees, and society alike.
Past Coverage
Qiming Weekly | Qiming Venture Partners Portfolio News & Updates Vol. 33, 2025 Qiming Stars | He Wang of Galaxy Universal: Focused on Developing Embodied AI Multimodal Large Models for General-Purpose Robots, Delivering Cross-Domain Generalization Solutions
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management of $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in technology and healthcare innovation.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies. More than 210 of these have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.